Thierry Virolle Selected Research

Glioblastoma (Glioblastoma Multiforme)

10/2023	Structure-Based Design of a Lead Compound Derived from Natural Schweinfurthins with Antitumor Properties That Target Oxysterol-Binding Protein.
1/2023	Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
10/2022	Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase.
1/2021	SETMAR Shorter Isoform: A New Prognostic Factor in Glioblastoma.
1/2019	Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia.
1/2018	Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness.
1/2017	A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.
1/2017	Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth.
5/2016	A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thierry Virolle Research Topics

Disease

9	Glioblastoma (Glioblastoma Multiforme) 10/2023 - 05/2016
7	Neoplasms (Cancer) 11/2023 - 07/2003
5	Glioma (Gliomas) 11/2023 - 04/2011
4	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2016
2	Hypoxia (Hypoxemia) 01/2019 - 07/2005
2	Prostatic Neoplasms (Prostate Cancer) 07/2003 - 04/2003
1	Neoplasm Metastasis (Metastasis) 01/2016
1	Ectodermal Dysplasia (Aplasia Cutis Congenita) 04/2010
1	Melanoma (Melanoma, Malignant) 07/2005

Drug/Important Bio-Agent (IBA)

4	Transcription Factors (Transcription Factor)IBA 01/2018 - 07/2003
2	Temozolomide (Temodar)FDA LinkGeneric 10/2023 - 01/2023
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2005
2	Amino Acids FDA Link 01/2017 - 01/2016
2	Early Growth Response Protein 1IBA 05/2016 - 04/2003
1	Formaldehyde (Formol)FDA Link 11/2023
1	ParaffinIBA 11/2023
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 10/2023
1	SulfurtransferasesIBA 10/2022
1	A-factor (Streptomyces)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Adenosine (Adenocard)FDA LinkGeneric 01/2019
1	prostatic acid phosphataseIBA 01/2019
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2019
1	ChromatinIBA 01/2018
1	histone H3 trimethyl Lys4IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2017
1	gamma-Aminobutyric Acid (GABA)IBA 01/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 04/2011
1	Hypoxia-Inducible Factor 1IBA 07/2005
1	Microphthalmia-Associated Transcription FactorIBA 07/2005
1	alpha-MSHIBA 07/2005
1	Messenger RNA (mRNA)IBA 07/2005
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2005
1	OligonucleotidesIBA 07/2003
1	Antisense OligonucleotidesIBA 07/2003
1	Cyclin D2IBA 04/2003

Therapy/Procedure

6	Therapeutics 01/2023 - 07/2003
1	Aftercare (After-Treatment) 01/2021
1	Radiotherapy 01/2016